In a collaboration with Access Biologicals, GigaGen is now recruiting donors who have convalesced from COVID-19. GigaGen will begin developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. The therapy known as rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin) is far more scalable than plasma-based methods and capable of creating a drug that can treat millions.
Read the full story here
